These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24026631)

  • 1. Probabilistic mapping of the health status measure SF-12 onto the health utility measure EQ-5D using the US-population-based scoring models.
    Le QA
    Qual Life Res; 2014 Mar; 23(2):459-66. PubMed ID: 24026631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample.
    Le QA; Doctor JN
    Med Care; 2011 May; 49(5):451-60. PubMed ID: 21422961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.
    Sullivan PW; Ghushchyan V
    Med Decis Making; 2006; 26(4):401-9. PubMed ID: 16855128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
    Yang Q; Yu XX; Zhang W; Li H
    Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
    Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
    Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.
    Gray AM; Rivero-Arias O; Clarke PM
    Med Decis Making; 2006; 26(1):18-29. PubMed ID: 16495197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
    Wolfe F; Michaud K; Wallenstein G
    J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population.
    Kim SH; Kim SO; Lee SI; Jo MW
    Health Qual Life Outcomes; 2014 Sep; 12():145. PubMed ID: 25248494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome.
    Rivero-Arias O; Ouellet M; Gray A; Wolstenholme J; Rothwell PM; Luengo-Fernandez R
    Med Decis Making; 2010; 30(3):341-54. PubMed ID: 19858500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?
    Rowen D; Brazier J; Roberts J
    Health Qual Life Outcomes; 2009 Mar; 7():27. PubMed ID: 19335878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map.
    Franklin M; Payne K; Elliott RA
    Med Decis Making; 2018 Jan; 38(1):79-94. PubMed ID: 29056069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.